AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8998395
Drug: Mirtazapine 20
RxNorm normalized name: Mirtazapine 20 mg in 1 g TOPICAL OINTMENT [Mirataz]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine 20 mg/day (titrated up to 60 mg/day)
Trial: 8998395
Drug: Doxepin 75
RxNorm normalized name: doxepin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxepin 75 mg/day (titrated up to 300 mg/day)
Trial: 31451252
Drug: Nutrition Intervention
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutrition Intervention (NI) - EPA-enriched nutrition supplement (2 bottles/day, 550 kcal/day) during NACRT
Trial: 30379936
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose pioglitazone (15 mg/day)
Trial: 30379936
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose pioglitazone (7.5 mg/day)
Trial: 24182347
Drug: sPD-1 concentrations
RxNorm normalized name: 5'-cEtG-sp-cEt5MeU-sp-cEt5MeU-sp-dT-sp-dA-sp-dT-sp-dT-spdA-sp-dT-sp-dA-sp-dG-sp-dG-sp-dG-sp-cEt5MeC-sp-cEt5MeU-sp-cEt5MeU-3'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sPD-1 concentrations in early RA (median 0.421 ng/mL, IQR 0.04-2.560 ng/mL)
Trial: 20560112
Drug: Immulina® (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immulina® (400 mg/day) for seven days
Trial: 20560112
Drug: Immulina® (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immulina® (200 mg/day) for seven days
Trial: 20560112
Drug: Immulina® (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immulina® (200 mg and 400 mg per day) for seven days
Trial: 10470387
Drug: Group P50:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group P50: propofol 1% 10 ml/thiopentone 2.5% 10 ml
Trial: 10470387
Drug: Group P75:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group P75: propofol 1% 15 ml/thiopentone 2.5% 5 ml
Trial: 9156906
Drug: Dexamethasone (optimal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (optimal dose)
Trial: 1862227
Drug: Combined regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined regimen of intramniotic prostaglandin (PG) F2a injection and intracervical laminaria tents (group A, 50 women)
Trial: 1862227
Drug: Intramniotic PGF2a
RxNorm normalized name: PGF2A THAM
DrugBank: Dinoprost tromethamine (DB01160)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramniotic PGF2a injection only (group B, 51 women)
Trial: 1862227
Drug: Laminaria tents
RxNorm normalized name: Laminaria digitata preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laminaria tents followed by intracervical PGF2a tablets insertion (group C, 27 women)
Trial: 6134547
Drug: Intramuscular papaveretum
RxNorm normalized name: papaveretum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular papaveretum
Trial: 21859051
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg melatonin nightly for 30 days
Trial: 19008077
Drug: Valacyclovir 1
RxNorm normalized name: valacyclovir 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir 1 g twice daily (n=24)
Trial: 11248761
Drug: Amlodipine (5mg/daily)
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine (5mg/daily)
Trial: 11248761
Drug: Nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS (30mg/daily)
Trial: 30206690
Drug: Remifentanil (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (0.5 µg/kg/min)
Trial: 23418465
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of ADVAX (DNA vaccine) + 2 doses of TBC-M4 (recombinant MVA) in Group A
Trial: 23418465
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of TBC-M4 (recombinant MVA) in Group B
Trial: 12117879
Drug: Folate supplementation
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folate supplementation (2 mg folic acid per day for three months)
Trial: 1983112
Drug: nizatidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nizatidine (300 mg h.s.)
Trial: 1983112
Drug: famotidine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: famotidine (40 mg h.s.)
Trial: 7016432
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg of 15-methyl-PGF2 alpha methyl ester in a vaginal suppository
Trial: 27866454
Drug: Pemetrexed continuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed continuation maintenance therapy
Trial: 24140442
Drug: Prolonged release
RxNorm normalized name: EYE DROPS, PROLONGED RELEASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged release oxycodone-naloxone (5.0 mg oxycodone, 2.5 mg naloxone, twice per day, up-titrated to a maximum of 40 mg oxycodone, 20 mg naloxone, twice per day)
Trial: 24140442
Drug: Prolonged release
RxNorm normalized name: EYE DROPS, PROLONGED RELEASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged release oxycodone-naloxone (during open-label extension phase)
Trial: 24140442
Drug: Prolonged release
RxNorm normalized name: EYE DROPS, PROLONGED RELEASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged release oxycodone-naloxone
Trial: 21873926
Drug: Corneal refractive
RxNorm normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corneal refractive therapy
Trial: 19188184
Drug: p53 synthetic
RxNorm normalized name: Camphor (synthetic)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p53 synthetic long peptide (p53-SLP) vaccine, administered twice
Trial: 17595592
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy (HT) with estradiol patches (50 microg/24 h) and oral medroxyprogesterone acetate (2.5 mg/d)
Trial: 9672273
Drug: Tamoxifen 20
RxNorm normalized name: tamoxifen 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 20 mg per day for 5 years
Trial: 9672273
Drug: Tamoxifen among
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen among women using hormone-replacement therapy
Trial: 9672273
Drug: Placebo among
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo among women using hormone-replacement therapy
Trial: 8023775
Drug: L-propionylcarnitine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-propionylcarnitine (15 mg/kg)
Trial: 3076382
Drug: Total lymphoid
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total lymphoid irradiation (TLI) (radiation dose, 20-30 Gy)
Trial: 19271065
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion (Group P)
Trial: 19271065
Drug: Desflurane inhalation
RxNorm normalized name: Desflurane Inhalation Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desflurane inhalation (Group D)
Trial: 10867454
Drug: Simple closure
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple closure with postsurgery medical treatment (proton pump inhibitors for 1 month)
Trial: 10867454
Drug: Vagotomy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vagotomy and pyloroplasty with no additional medical treatment
Trial: 9089001
Drug: Demotussol Hustensirup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Demotussol Hustensirup (syrup)
Trial: 9089001
Drug: Sinecod Sirup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinecod Sirup (syrup)
Trial: 9089001
Drug: Demotussol Tabletten
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Demotussol Tabletten (tablet)
Trial: 9089001
Drug: Demotussol Hustentropfen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Demotussol Hustentropfen (solution)
Trial: 8404115
Drug: Smoking intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking intervention with daily use of a metered-dose inhaler with ipratropium bromide
Trial: 8404115
Drug: Smoking intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking intervention with inhalation of placebo
Trial: 2957569
Drug: Org OD
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Org OD 14 (2.5 mg/day for 6 months)
Trial: 28306636
Drug: perindopril/indapamide/amlodipine 5/1.25/5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: perindopril/indapamide/amlodipine 5/1.25/5 mg
Trial: 28306636
Drug: perindopril/indapamide/amlodipine 10/2.5/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: perindopril/indapamide/amlodipine 10/2.5/10 mg (up-titration)
Trial: 28306636
Drug: perindopril/indapamide 5/1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: perindopril/indapamide 5/1.25 mg
Trial: 21504973
Drug: Muscadine grape
RxNorm normalized name: Muscadine Grape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muscadine grape seed supplementation (1300 mg daily)
Trial: 15888038
Drug: Steroid avoidance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid avoidance regimen (no steroids at all)
Trial: 15888038
Drug: Steroid withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid withdrawal regimen (steroids for the first 3 months)
Trial: 27214389
Drug: Glatiramer acetate
RxNorm normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glatiramer acetate treatment
Trial: 27020837
Drug: Fentanyl sublingual
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl sublingual spray (FSS) effective dose (100-1600 µg)
Trial: 15479896
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg oral prednisolone/day for three weeks
Trial: 7530437
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of alpha fetoprotein and free beta human chorionic gonadotropin
Trial: 2902114
Drug: Levocabastine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocabastine (0.5 mg/ml, one drop twice a day)
Trial: 2902114
Drug: Screening test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening test (no medication)
Trial: 25322606
Drug: Propofol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2 mg/kg) intravenous injection
Trial: 20428741
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol (400 ug)
Trial: 18275768
Drug: High-dose corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose corticosteroids and immunosuppressive drugs (cyclophosphamide)
Trial: 2123115
Drug: 3.75 mg
RxNorm normalized name: zopiclone 3.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 mg leuprorelin
Trial: 2123115
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg leuprorelin
Trial: 30652777
Drug: Brief Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief Group Intervention (BGI) with four group sessions, weekly meetings
Trial: 27679533
Drug: FAST‐MAG clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAST‐MAG clinical trial (Field Administration of Stroke Therapy‐Magnesium)
Trial: 24523488
Drug: Dose-dilution protocol
RxNorm normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dilution protocol
Trial: 14564193
Drug: Increased dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased dose of peritoneal small molecule clearance delivered by chronic ambulatory peritoneal dialysis
Trial: 30104718
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy and autologous stem cell transplantation
Trial: 9058342
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg itraconazole (one-day monthly prophylaxis for six months)
Trial: 8375881
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (40 mg elemental iron/day) for six months
Trial: 3091138
Drug: Oestrogen (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestrogen (160 mg polyestradiol phosphate intramuscularly every month for the first three months, then 80 mg monthly, plus ethinyloestradiol 1 mg by mouth daily for the first two weeks, then 150 micrograms daily)
Trial: 25066223
Drug: MCT +
RxNorm normalized name: MCT
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCT + treatment as usual (TAU)
Trial: 18540734
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy for pain (P)
Trial: 18540734
Drug: Mindfulness meditation
RxNorm normalized name: benzalkonium chloride Topical Foam [Meditize]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness meditation and emotion regulation therapy (M)
Trial: 15846228
Drug: Micronized estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Micronized estradiol (E2) 1 mg/day
Trial: 15846228
Drug: E2 1
RxNorm normalized name: PGE2 10 MG Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 1 mg/day + MPA 10 mg/day
Trial: 15846228
Drug: Micronized progesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized progesterone (P4) 300 mg/day
Trial: 15846228
Drug: Norethindrone (NET)
RxNorm normalized name: Norethindrone
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norethindrone (NET) 1 mg/day
Trial: 15846228
Drug: Calcium and
RxNorm normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium and vitamin D supplementation (1000 mg of calcium and 400 IU of vitamin D/day)
Trial: 7752832
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 (CoQ) therapy
Trial: 7752832
Drug: Anthracyclines (ANT)
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anthracyclines (ANT) without CoQ therapy
Trial: 3281412
Drug: Metoprolol 200
RxNorm normalized name: metoprolol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 200 mg daily for the first 3 months
Trial: 3281412
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for the first 3 months
Trial: 3281412
Drug: Metoprolol (early
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (early treatment, ≤ 8 hours after onset of pain)
Trial: 3281412
Drug: Placebo (early
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (early treatment, ≤ 8 hours after onset of pain)
Trial: 3281412
Drug: Metoprolol (late
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (late treatment, > 8 hours after onset of pain)
Trial: 3281412
Drug: Placebo (late
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (late treatment, > 8 hours after onset of pain)
Trial: 20209976
Drug: Medication (Yueyueshu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (Yueyueshu Granules)
Trial: 17549294
Drug: Rivaroxaban (5-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (5-60 mg, oral, twice-daily)
Trial: 17549294
Drug: Enoxaparin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (40 mg once daily before THR, 30 mg bid after TKR)
Trial: 17549294
Drug: Rivaroxaban (5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (5-20 mg)
Trial: 11477494
Drug: Exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise training (8 week supervised program, aerobic exercise at 75% VO(2) peak, 45 min, twice a week; intermittent exercise once a week)
Trial: 9495222
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir (1000 mg every 8 hours) with zidovudine (AZT)
Trial: 9495222
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir (1000 mg every 8 hours) with didanosine (ddI) administered sequentially (2 hours before ganciclovir)
Trial: 9495222
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir (1000 mg every 8 hours) with didanosine (ddI) administered simultaneously
Trial: 9495222
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir (1000 mg every 8 hours) with probenecid
Trial: 9495222
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir (1000 mg every 8 hours) administered 2 hours after didanosine (ddI)
Trial: 9495222
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir (1000 mg every 8 hours) with no coadministration
Trial: 2902319
Drug: Clonidine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.1 mg/m2 by mouth, nightly for 6 months)
Trial: 29939961
Drug: Interoceptive Exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interoceptive Exposure (IE) therapy
Trial: 28743198
Drug: Relaxation Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation Therapy (RT)
Trial: 28614188
Drug: Sham opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham opioid solution (NaCl) with verbal instruction that it reduces pain and improves physical capacity
Trial: 28614188
Drug: Inactive solution
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive solution (NaCl) presented as an effective treatment
Trial: 23347341
Drug: AndroGel 1%
RxNorm normalized name: Androgel 1% Transdermal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AndroGel 1% 5 g, 7.5 g, or 10 g once daily for 6 months (Study 1)
Trial: 23347341
Drug: AndroGel 1%
RxNorm normalized name: Androgel 1% Transdermal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AndroGel 1% 7.5 g once daily titrated as needed (Study 2)
Trial: 23347341
Drug: AndroGel 1%
RxNorm normalized name: Androgel 1% Transdermal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AndroGel 1% 5 g once daily (Study 3)
Trial: 19296208
Drug: Nasal powder
RxNorm normalized name: NASAL POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal powder formulation
Trial: 19296208
Drug: Commercial nasal
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercial nasal liquid spray
Trial: 9079231
Drug: Sublingual tablet
RxNorm normalized name: Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual tablet
Trial: 18031872
Drug: HBsAg with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBsAg with AS02B adjuvant candidate vaccine plus lamivudine daily for 52 weeks
Trial: 18031872
Drug: lamivudine daily
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: lamivudine daily alone
Trial: 14727216
Drug: Indinavir (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir (800 mg) and Ritonavir (100 mg) twice a day with Rifampin (300 mg every day for 4 days)
Trial: 9629648
Drug: Group sequential
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group sequential method based on the sequential conditional probability ratio test
Trial: 9629648
Drug: Group sequential
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group sequential method
Trial: 8067842
Drug: Heparin-coated membrane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated membrane oxygenators (100 IU/kg heparin)
Trial: 8067842
Drug: Noncoated control
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Noncoated control membrane oxygenators (300 IU/kg heparin)
Trial: 31489293
Drug: Cisplatin 40
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 40 mg/m2 (weekly)
Trial: 31489293
Drug: Cisplatin 100
RxNorm normalized name: CISPLATIN 100MG/VIL (PF) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 100 mg/m2 (3 weekly)
Trial: 25908501
Drug: Therapeutic massage
RxNorm normalized name: All Body Powerful Therapeutic Massager
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic massage (effleurage, kneading, and trigger point therapy) for 10 minutes, four times per week for 4 weeks
Trial: 16952489
Drug: Tariquidar (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tariquidar (150 mg over 30 minutes)
Trial: 8406149
Drug: Liquid fibre
RxNorm normalized name: Fiore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid fibre (250 ml)